Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $51.92 which represents a decrease of $-1.00 or -1.89% from the prior close of $52.92. The stock opened at $52.68 and ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback